Latest news with #LDD
Business Wire
2 hours ago
- Business
- Business Wire
RXST CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of RxSight, Inc. Investors
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP ('GPM'), announces that it has filed a class action lawsuit in the United States District Court for the Central District of California, captioned Makaveev v. RxSight, Inc., et al., Case No. 8:25-cv-01596, on behalf of persons and entities that purchased or otherwise acquired RxSight, Inc. ('RxSight' or the 'Company') (NASDAQ: RXST) securities between , inclusive (the 'Class Period'). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the 'Exchange Act'). Investors are hereby notified that they have 60 days from the date of this notice to move the Court to serve as lead plaintiff in this action. IF YOU SUFFERED A LOSS ON YOUR RXSIGHT INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On July 8, 2025, after the market closed, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in LDD sales, and LAL utilization, and overall revenue. The Company also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint. The Company's Chief Executive Officer, Ronald Kurtz, also disclosed that '[a]doption challenges over the last few quarters have been a primary reason for the LDD stall.' On this news, RxSight's stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025, on unusually heavy trading volume. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company was experiencing 'adoption challenges' and/or structural issues resulting in declines in sales and utilization; (2) Defendants had overstated the demand for RxSight's products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you purchased or otherwise acquired RxSight securities during the Class Period, you may move the Court no later than 60 days from the date of this notice to ask the Court to appoint you as lead plaintiff. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
a day ago
- Business
- Business Wire
RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights
LOS ANGELES--(BUSINESS WIRE)-- The DJS Law Group announces that it is investigating claims on behalf of investors of RxSight, Inc. ('RxSight' or 'the Company') (NASDAQ: RXST) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. RxSight reported its financial results for the second quarter of 2025 on July 9, 2025. The Company reported declines in key metrics including sales of Light Delivery Devices ('LDD') along with a decline in total revenue across the organization. The Company also lowered its guidance for its full year financial performance, blaming the change in part on 'adoption challenges' that have caused an 'LDD stall.' Based on its financial performance, shares of RxSight fell by just under 38% on the same day. If you are a shareholder who suffered a loss, contact us to participate. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
4 days ago
- Business
- Business Wire
RXST Investors Have Opportunity to Join RxSight, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of RxSight, Inc. ('RxSight' or 'the Company') (NASDAQ: RXST) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. RxSight reported its Q2 2025 financial results on July 9, 2025. The Company revealed declines in Light Delivery Devices ('LDD') sales and light adjustable intraocular lenses ('LAL') utilization, along with an overall revenue decline. The Company lowered its guidance for full year 2025, claiming that 'Adoption challenges over the last few quarters have been a primary reason for the LDD stall.' Based on this news, shares of RxSight fell by 37.8% on July 9, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
11-07-2025
- Business
- Business Wire
RxSight, Inc. (RXST) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of RxSight, Inc. ('RxSight' or the 'Company') (NASDAQ: RXST) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN RXSIGHT, INC. (RXST), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On July 9, 2025, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in Light Delivery Devices ('LDD') sales, light adjustable intraocular lenses ('LAL') utilization, and overall revenue. The Company also lowered its Full Year 2025 guidance by approximately $42.5 million at the midpoint and stated that '[a]doption challenges over the last few quarters have been a primary reason for the LDD stall.' On this news, RxSight's stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025, thereby injuring investors. Contact Us to Participate or Learn More: If you purchased RxSight securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith 3070 Bristol Pike, Suite 112 Bensalem, Pennsylvania 19020 Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
20-05-2025
- Business
- Yahoo
Wells Fargo Upgrades RxSight (RXST), Sees LAL Technology as Undervalued
Wells Fargo upgraded RxSight Inc. (NASDAQ:RXST) from Equal Weight to Overweight on Monday, while raising its price target from $17 to $25 due to an attractive valuation at the current stock price. Wells Fargo believes that the market is undervaluing RxSight's differentiated light-adjustable lens/LAL technology and its potential for incremental market growth. A close up detail of a cataract surgery instrument in the hand of a cataract doctor. The firm emphasizes RxSight's first-mover advantage in this market. While major players have indicated interest in the adjustable intraocular lens/IOL market, Wells Fargo maintains that the development timelines are extensive and hence notes RxSight's decade-plus journey to bring LAL to the US market and expects a considerable delay before competitors can enter. RxSight Inc. (NASDAQ:RXST) is a commercial-stage medical tech company that engages in the research and development, manufacture, and sale of light-adjustable intraocular lenses/LAL used in cataract surgery in the US. It offers the RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. RxSight is ahead of schedule with a software update for its Light Delivery Device/LDD procedures and has received full regulatory approval for its LAL Plus and LDD products in South Korea, with anticipated UK approval in Q2 2025. While we acknowledge the potential of RXST to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RXST and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
